Ardelyx (NASDAQ:ARDX) Stock Picked Up by Analysts at TD Cowen

Analysts at TD Cowen initiated coverage on shares of Ardelyx (NASDAQ:ARDX) in a research report issued to clients and investors on Wednesday, Zacks reports. The brokerage set a “strong-buy” rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also issued reports on the company. HC Wainwright reissued a “buy” rating and set a $13.00 price target on shares of Ardelyx in a research note on Friday, August 7th. Zacks Research raised Ardelyx from a “strong sell” rating to a “hold” rating in a research report on Friday, October 16th. Piper Sandler reduced their target price on Ardelyx from $16.00 to $15.00 and set an “overweight” rating on the stock in a research note on Monday, August 17th. Wedbush reiterated an “outperform” rating and issued a $9.00 target price on shares of Ardelyx in a research note on Tuesday, August 18th. Finally, BTIG Research decreased their target price on Ardelyx from $17.00 to $14.00 and set a “buy” rating for the company in a research report on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Ardelyx currently has an average rating of “Moderate Buy” and a consensus price target of $13.90.

Ardelyx Stock Down 9.1%

Shares of NASDAQ ARDX opened at $2.99 on Wednesday. The company has a debt-to-equity ratio of 1.54, a current ratio of 3.45 and a quick ratio of 3.15. The company has a market cap of $751.60 million, a P/E ratio of -13.59 and a beta of 0.79. Ardelyx has a 1 year low of $2.95 and a 1 year high of $8.40. The firm has a 50-day simple moving average of $3.37 and a two-hundred day simple moving average of $5.26.

Ardelyx (NASDAQ:ARDX) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.02). Ardelyx had a negative net margin of 11.85% and a negative return on equity of 35.30%. The business had revenue of $120.88 million for the quarter, compared to analysts’ expectations of $121.03 million. During the same quarter last year, the firm earned ($0.08) EPS. The firm’s quarterly revenue was up 34.3% on a year-over-year basis. Research analysts anticipate that Ardelyx will post -0.20 earnings per share for the current year.

Insider Buying and Selling at Ardelyx

In other news, insider Laura A. Williams sold 10,739 shares of the company’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $3.86, for a total value of $41,452.54. Following the completion of the sale, the insider owned 367,456 shares of the company’s stock, valued at approximately $1,418,380.16. This represents a 2.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider John E. Bishop sold 19,750 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $3.86, for a total transaction of $76,235.00. Following the transaction, the insider owned 317,095 shares in the company, valued at approximately $1,223,986.70. This represents a 5.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 126,059 shares of company stock worth $486,588. 5.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Ardelyx

A number of large investors have recently bought and sold shares of ARDX. Knott David M Jr bought a new position in shares of Ardelyx in the 1st quarter worth $1,240,000. AIGH Capital Management LLC purchased a new stake in shares of Ardelyx during the 2nd quarter worth $16,320,000. Rubric Capital Management LP bought a new stake in Ardelyx during the first quarter valued at about $11,147,000. Clay Northam Wealth Management LLC bought a new stake in Ardelyx during the second quarter valued at about $1,704,000. Finally, J. Goldman & Co LP bought a new stake in Ardelyx during the second quarter valued at about $8,057,000. Institutional investors own 58.92% of the company’s stock.

Trending Headlines about Ardelyx

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Ardelyx reported third-quarter EPS of $0.00, ahead of analysts’ expectation of a $0.02 loss. Product revenue was $125.5 million, while total revenue of $127.66 million came in slightly below estimates; revenue grew 21% year over year. The company maintained its 2026 IBSRELA revenue outlook of $350 million to $370 million. Ardelyx Q3 earnings
• Positive Sentiment: HC Wainwright raised its Q4 2026 EPS estimate to $0.04 from $0.01 and its FY2026 estimate to a loss of $0.18 per share from a loss of $0.26. The firm kept its Buy rating and $13 price target. TD Cowen also reaffirmed its Buy rating. TD Cowen rating
• Neutral Sentiment: The company completed enrollment in its Phase 3 ACCEL trial of IBSRELA for adults with chronic idiopathic constipation, an operational milestone ahead of future trial updates. ACCEL trial enrollment
• Negative Sentiment: HC Wainwright cut its EPS forecasts for FY2027, FY2029 and FY2030, including a reduction for FY2029 to $1.18 from $1.56. The longer-term estimate revisions temper the improvement in its near-term outlook.
• Negative Sentiment: Multiple law firms publicized a securities class action against Ardelyx, with a November 16 lead-plaintiff deadline. The lawsuit alleges the company misrepresented payer access and reimbursement barriers affecting IBSRELA and XPHOZAH; these claims are allegations, not established findings. Litigation adds uncertainty and reputational risk. Class action allegations

Ardelyx Company Profile

Ardelyx, Inc is a biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal and cardiorenal diseases. The company’s platform is centered on regulating ion transport in the gut, with the goal of addressing conditions that are inadequately served by existing treatments.

Ardelyx’s marketed products include IBSRELA (tenapanor), an oral treatment for adults with irritable bowel syndrome with constipation, and XPHOZAH (tenapanor), a therapy designed to reduce serum phosphorus in adults with chronic kidney disease on dialysis who have an inadequate response to, or are intolerant of, phosphate binders.